tnx-832
mAbexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2004 (NCT01438853)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Coagulation factor IIIINHIBITOR
F3 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- tnx-832
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01438853 | Phase 1 | Dec 1, 2004 | Altor Bioscience, Genentech, Tanox |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Altor Bioscience | For profit | 1 | 1 | 1 | 2004 |
| Genentech | For profit | 1 | 0 | 1 | 2004 |
| Tanox | For profit | 1 | 0 | 1 | 2004 |
3 organizations
Page 1 / 1